Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 3:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 22,242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
Interventions: Observational; Other
Lead sponsor: Escape Bio, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Culver City, California

Conditions: Healthy Volunteer
Interventions: BIIB091, Moxifloxacin, BIIB091-matched Placebo, Moxifloxacin-matched Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Older Adult
Interventions: OSC-; Behavioral
Lead sponsor: Brigham Young University; Other
Eligibility: 65 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Provo, Utah

Conditions: Liver Cirrhosis, Hepatic Cirrhosis
Interventions: IDN-6556, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 28
States / cities: Birmingham, Alabama • La Jolla, California • Loma Linda, California + 21 more

Conditions: Breast Cancer
Interventions: CHESS (Comprehensive Health Enhancement Support System), CHESS; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 3
States / cities: Hartford, Connecticut • Houston, Texas • Madison, Wisconsin

Conditions: Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome, CLOVES Syndrome
Interventions: KP-001, Placebo; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Progressive Multiple Sclerosis, Fatigue
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple System Atrophy (MSA)
Interventions: ONO-2808, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 30
States / cities: Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more

Conditions: Alcohol Consumption
Interventions: Lab-based Cue Reactivity Personalized Feedback Intervention (PFI); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 24 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pain
Interventions: Ketamine, Opioids; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: Oxaliplatin, Leucovorin, Fluorouracil, Ziv-aflibercept; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Healthy Adult
Interventions: BMS-986142, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Suicidal Ideation
Interventions: Nabilone, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prader-Willi Syndrome
Interventions: Pitolisant oral tablets, Placebo oral tablet; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 13
States / cities: San Diego, California • San Ramon, California • Santa Monica, California + 10 more

Conditions: Cryobiopsy of Peripheral Lymph Nodes
Interventions: Cryobiopsy, Cryobiopsy, Core Needle Biopsy; Procedure · Device
Lead sponsor: San Antonio Uniformed Services Health Education Consortium; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Preterm Infant
Interventions: Therapist skin-to-skin Care, Contingent parent's voice exposure, Parental skin-to-skin care, Recorded parent's voice; Behavioral · Device
Lead sponsor: Emory University; Other
Eligibility: 32 Weeks to 36 Weeks
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia • Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Advanced Solid Tumors That Are MTAP Deficient
Interventions: AZD3470, Datopotamab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: San Francisco, California • West Hollywood, California • New Haven, Connecticut + 5 more

Conditions: Control, 1 Night Recovery Sleep, 3 Nights Recovery Sleep, 5 Nights Recovery Sleep
Interventions: Sleep; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 50 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Optimized Treatment (OPT); Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 6
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Lurasidone HCl, Risperidone; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more

Conditions: Exercise Performance Recovery
Interventions: XSurge, Placebo: Microcrystalline Cellulose, Control: No supplementation; Dietary Supplement · Other
Lead sponsor: Kemin Foods LC; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Dietary Change, Obesity & Overweight, Food Acceptance
Interventions: Pistachios, Dual-energy X-ray absorptiometry (DEXA) scans; Dietary Supplement · Procedure
Lead sponsor: Ian J. Neeland, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Clevland, Ohio

Conditions: Pain
Interventions: Forgionei-Barber pressure-pain stimulator, Concentric Exercise, isometric exercise; Device · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants

Heart Rate Variability Biofeedback in Older Adults

A Study of IDN-6556 in Subjects With Liver Cirrhosis

Component and Couple Analysis of Cancer Communications

A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

A Study of Oxidative Pathways in MS Fatigue

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Testing Brief Personalized Feedback Integrating Lab-based Alcohol Cue Information

Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Cryobiopsy for Suspected Malignant Peripheral Lymphadenopathy

Trial to Improve Multisensory Neural Processing, Language & Motor Outcomes in Preterm Infants

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Neurobehavioral Effects of Partial Sleep Deprivation

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

The Effect of XSurge Supplementation on Biomarkers and Performance From High Intensity Resistance Exercise

Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy

Exercise-induced Hypoalgesia After Comparative Forms of Exercise